Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Total Current Liabilities (2022 - 2025)

Historic Total Current Liabilities for TriSalus Life Sciences (TLSIW) over the last 4 years, with Q3 2025 value amounting to $10.9 million.

  • TriSalus Life Sciences' Total Current Liabilities rose 1000.2% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year increase of 1000.2%. This contributed to the annual value of $10.2 million for FY2024, which is 3036.02% down from last year.
  • Latest data reveals that TriSalus Life Sciences reported Total Current Liabilities of $10.9 million as of Q3 2025, which was up 1000.2% from $9.3 million recorded in Q2 2025.
  • Over the past 5 years, TriSalus Life Sciences' Total Current Liabilities peaked at $32.4 million during Q4 2022, and registered a low of $1.7 million during Q2 2022.
  • Its 4-year average for Total Current Liabilities is $10.1 million, with a median of $9.9 million in 2024.
  • Over the last 5 years, TriSalus Life Sciences' Total Current Liabilities had its largest YoY gain of 38621.92% in 2023, and its largest YoY loss of 5460.95% in 2023.
  • Over the past 4 years, TriSalus Life Sciences' Total Current Liabilities (Quarter) stood at $32.4 million in 2022, then tumbled by 54.61% to $14.7 million in 2023, then plummeted by 30.36% to $10.2 million in 2024, then increased by 6.67% to $10.9 million in 2025.
  • Its Total Current Liabilities was $10.9 million in Q3 2025, compared to $9.3 million in Q2 2025 and $11.8 million in Q1 2025.